| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Shionogi bolsters rare disease portfolio with $2bn IntraBio buyout | ||
| Di | Lilly deepens ties with Gate Bioscience in $870m deal expansion | ||
| Di | Alector shares up after sealing $1.27bn Roche Parkinson's disease license deal | ||
| Di | CSL and Alentis ink $1.5bn partnership to progress antifibrotic drug | ||
| Di | Pacira partners with Molteni for Exparel commercialisation | ||
| Di | AstraZeneca opens new R&D centre in Cambridge, US | ||
| Mo | Scientists claim Nobel Prize for approach behind light-activated gene therapy | ||
| Mo | FDA approves expanded indication for Lilly's Jaypirca | ||
| Mo | Bayer plans $2.2bn pharmaceutical manufacturing facility in Ohio, US | ||
| Fr | AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact | ||
| Do | Varda pockets $251m to back space-based pharma processing mission | ||
| Do | Sanofi and Regeneron expand immunology partnership to the tune of $8bn | ||
| Do | Bristol Myers Squibb secures expanded US approval for Camzyos | ||
| Do | BioMarin and Profluent partner on AI-designed enzyme therapies | ||
| 30.09. | Atossa plans shareholder stake in potential PRV proceeds | ||
| 30.09. | OBIO marks $704m funding milestone for Canadian health tech ventures | ||
| 30.09. | Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab | ||
| 29.09. | Novo outlays $2.6bn in Hengrui deal to bolster oral obesity pipeline | ||
| 29.09. | MSD bets $2.13bn on SciBrunch's KRAS (ON) inhibitor | ||
| 29.09. | AstraZeneca to invest $2bn in Summit for ADC combination therapies | ||
| 29.09. | Tolerance Bio signs $560m worldwide TLB-33 deal with Tanabe Pharma | ||
| 28.09. | AbbVie lands FDA approval for next-generation Parkinson's drug, Juvmo | ||
| 28.09. | Novo inks $1.33bn long-lasting injectable pact with Sweden-based Nanexa | ||
| 28.09. | Daiichi Sankyo, MSD withdraw cancer drug application | ||
| 28.09. | Mirum and Incyte's Atebrioz approved for FOP in US |